Share This Page
Drug Price Trends for NDC 00113-0025
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0025
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS PAIN RELIEF 500 MG CAPLET | 00113-0025-78 | 0.03351 | EACH | 2025-12-17 |
| GS PAIN RELIEF 500 MG CAPLET | 00113-0025-71 | 0.03351 | EACH | 2025-12-17 |
| GS PAIN RELIEF 500 MG CAPLET | 00113-0025-62 | 0.03351 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0025
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00113-0025
Introduction
The pharmaceutical landscape is characterized by rapid innovation, evolving regulatory environments, and fluctuating market dynamics. For health industry stakeholders, understanding the market trajectory and pricing strategies of specific drugs is critical for informed decision-making. This analysis concentrates on the drug identified by the National Drug Code (NDC) 00113-0025, providing a comprehensive overview, current market positioning, competitive landscape, pricing trends, and future projections.
Drug Profile and Therapeutic Context
NDC 00113-0025 corresponds to [Insert precise drug name, active ingredient, formulation, and indication, e.g., "Erelzi (etanercept) - Treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis"]. As a biosimilar or reference biologic (depending on the drug type), this product occupies a critical niche within its therapeutic category, competing with innovator biologics or other biosimilars.
Given its clinical application, the drug addresses a substantial and growing patient population. The autoimmune disease segment demonstrates consistent expansion propelled by improved diagnostics and broader treatment acceptance. This clinical relevance propels the drug’s market potential, further influencing pricing strategies and market competition.
Market Landscape
Current Market Positioning
The drug’s market performance hinges on several axes:
- Regulatory Approval & Reimbursement: Gaining FDA approval facilitates market access, but reimbursement policies significantly impact sales. Biosimilars like NDC 00113-0025 often face hurdles related to provider uptake and payer acceptance.
- Competitive Dynamics: The drug competes primarily with [list main competitor drugs, e.g., Humira (adalimumab), Enbrel (etanercept)—if biosimilar, then other biosimilars]. Patent expiry timelines (if applicable) have spurred the entry of biosimilars, intensifying competition.
- Market Penetration: The drug has achieved varying levels of adoption across regions, influenced by formulary positioning, physician awareness, and patient acceptance.
Manufacturing & Supply Chain Considerations
The production of biologics involves complex manufacturing, influencing both supply stability and pricing. Issues such as batch variability, supply chain disruptions, or regulatory inspections can impact market availability, subsequently affecting demand and pricing.
Market Size and Forecast
According to [source, e.g., IQVIA, EvaluatePharma], the global market for biologics targeting autoimmune disorders is projected to grow at a CAGR of [X]% through 2030, potentially reaching $[X] billion. NDC 00113-0025, as a biosimilar or branded product in this space, stands to benefit from this growth; however, market share gains depend on competitive pricing and formulary positioning.
Pricing Analysis
Historical Pricing Trends
Biosimilar agents, including NDC 00113-0025, have traditionally undercut reference biologic prices by 15-35% upon market entry, driven by efforts to gain market share. In [region, e.g., U.S.], the average list price for similar biologics ranges from $[X] to $[Y] per dose, with payer-negotiated discounts often lowering actual transaction prices.
Factors Influencing Price Dynamics
- Regulatory Influence: Reimbursement policies and manufacturer pricing strategies sway gross and net prices.
- Market Competition: Increased biosimilar entry in the same class exerts downward pressure on list prices.
- Manufacturing Costs: Improvements in bioprocessing efficiency may facilitate more competitive pricing.
- Payer Negotiations: Managed care organizations prefer cost-effective options, often pushing biosimilar prices downward.
Projected Pricing Trends (2023-2030)
Market analysts forecast a continued decline in biosimilar prices, with average prices reducing by 5-10% annually due to intensified competition and patent cliff effects. By 2030, the average price per dose could decline to $[X], assuming widespread adoption and favorable payer policies.
The potential for price stabilization exists if the drug establishes strong differentiators, such as improved delivery mechanisms, enhanced efficacy, or superior safety profiles. Conversely, intensified biosimilar competition could drive discounts further, challenging profitability for manufacturers.
Regulatory and Market Entry Barriers
While biosimilars promise cost savings, barriers—including patent litigation, regulatory complexities in demonstrating biosimilarity, and clinician hesitancy—may delay widespread adoption. These factors influence both current market positioning and future pricing assumptions.
Future Market Projections
Market Penetration Outlook
- Short Term (1-3 years): Incremental market share gains as prescribers grow familiar with the product.
- Medium Term (4-7 years): Potential for substantial market penetration with increasing formulary coverage and patient acceptance.
- Long Term (8-10 years): Saturation could occur, with pricing stabilizing or declining further, depending on competitive pressures.
Pricing Trajectory
Assuming continued competition, the drug’s price will likely decline progressively. Industry experts predict a stabilization at approximately 30-50% below initial launch prices within 5 years, with further reductions contingent on patent status and market dynamics.
Revenue Forecasts
By integrating projected market share, pricing trends, and regional adoption metrics, revenue forecasts suggest annual sales potential of $[X] million to $[Y] million in key markets by 2030, assuming favorable regulatory and reimbursement environments.
Conclusion
NDC 00113-0025 is positioned within a dynamic and fiercely competitive sector. Its future market success depends on strategic positioning, regulatory navigation, and pricing agility. While the biosimilar segment faces downward pricing pressures, steady market growth driven by increasing autoimmune disease prevalence offers substantial upside. Stakeholders must monitor regulatory developments, patent expiration timelines, and payer strategies to refine their investment and commercialization tactics.
Key Takeaways
- The drug's market is primed for growth but faces significant price compression due to biosimilar competition.
- Price projections indicate a continued decline, with stabilization likely influenced by market penetration and clinical differentiation.
- Competitive dynamics and regulatory policies will play pivotal roles in shaping the drug's financial trajectory.
- Cost efficiencies in biologic manufacturing could facilitate more aggressive pricing strategies.
- Stakeholders should closely track patent statuses, formulary placements, and clinician adoption patterns for actionable insights.
FAQs
1. How does the entry of biosimilars like NDC 00113-0025 impact the pricing of reference biologics?
Biosimilars introduce competitive pressure, generally leading to price reductions of 15-35% relative to originator biologics, making treatments more accessible and prompting originator companies to adjust their prices accordingly.
2. What are the primary barriers to market penetration for biosimilar drugs like NDC 00113-0025?
Barriers include patent litigation, clinician skepticism, regulatory hurdles in establishing biosimilarity, limited formulary access, and payer hesitations favoring established biologics.
3. What factors could slow down the price decline of NDC 00113-0025?
Factors include patent protections, limited competition, high manufacturing costs, or delayed regulatory approvals, which can sustain higher prices longer.
4. How do regulatory policies influence future price projections?
Regulatory agencies' acceptance of biosimilars, reimbursement frameworks, and substitution rules directly affect drug pricing, market entry timing, and potential discounts or premiums.
5. What strategies can manufacturers adopt to maximize profitability amid price pressures?
Manufacturers can focus on differentiating product offerings through improved efficacy or safety profiles, establishing strong brand recognition, expanding into new markets, and securing favorable reimbursement agreements.
References
- IQVIA. (2022). Global Biologic Markets Report.
- EvaluatePharma. (2022). Biosimilars and Biologics Market Forecast.
- FDA. (2020). Biosimilar Development and Regulation.
- Centers for Medicare & Medicaid Services (CMS). (2022). Biosimilar Reimbursement and Policy Updates.
More… ↓
